The role of the phosphodiesterase type IV iso zyme (PDE IV) in the regulation of cerebrovascular tone was investigated in the canine basilar artery in vitro and in vivo. The PDE isozymes extracted from the canine basilar artery were isolated by diethylaminoethanol (DEAE) Sepharose affinity chromatography and identified based on sensitivity to isozyme-selective PDE inhibitors. [3HJcAMP hydrolysis was observed in one major and one minor peak of activity. The predominant peak was inhibited by the addition of cGMP (2S%), siguazodan (26%), rolipram (39%), and the combination of siguazodan and rolipram (9S%). Selective PDE IV inhibitors BRL 61063, rolipram, and denbufylline were equieffective inhibitors of [3HJ ccAMP hydrolysis mediated by PDE IV isolated from the canine basilar artery [concentrations producing SO% inhibi tion (ICsos) = 0.21 ± O.OS p.,M, 0.67 ± 0.23 p.,M, and 0.73 ± 0.16 p.,M, respectively]. In precontracted isolated ring segments of the canine basilar artery, selective PDE IV inhibitors produced potent and complete relaxation (ICsos <ISO nM). In contrast, zaprinast (a selective PDE V inhibi tor) and siguazodan (a selective PDE III inhibitor) pro-
The family of phosphodiesterase (POE) isozymes is responsible for the intracellular hydrolysis of cAMP and cOMPo Some members of the seven POE gene families differ in their structure, substrate speci ficity, sensitivity to selective inhibitors, and tissue dis-duced only weak relaxation of the basilar artery (ICsos = 4.S p.,M and > 10 p.,M, respectively). Vasorelaxation pro duced by PDE IV inhibitors was not altered by removing the endothelium, I-NAME, or adenosine receptor antago nism. In a canine model of acute cerebral vasospasm, all three selective PDE IV inhibitors reversed basilar artery spasm . produced by autologous blood without altering mean arterial blood pressure. In contrast, prolonged treat ment with BRL 61063 failed to alter the development of basilar spasm in the two hemorrhage canine models of chronic cerebral vasospasm. Denbufylline-induced relax ation in vitro was also significantly impaired in basilar arteries obtained from the model of chronic vasospasm.
In conclusion, PDE IV appears to be the predominant isozyme regulating vascular tone mediated by cAMP hy drolysis in cerebral vessels. In addition, vasorelaxation modulated by PDE IV is compromised in chronic cere bral vasospasm associated with subarachnoid hemorrhage.
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tribution (for review, see Beavo et a!., 1994) . POE III (a cAMP-preferring enzyme) is deficient in the brain, and the majority of cAMP hydrolysis is via the POE IV isozyme, where it is an important regulator of neuronal excitability and activity (Nemoz et a!., 1989; Challiss and Nicholson, 1990) . In this regard, selective POE IV inhibitors (i.e., denbufylline and rolipram) possess a variety of CNS effects, including anti-ischemic, antidepressant, and nootropic activity (Angersbach, 1991; Nicholson et a!., 1991) .
In peripheral arteries (e.g., rat and bovine aorta), membrane-bound and cytosolic POE III and POE IV catalyze cAMP hydrolysis (Nicholson et a!., 1991; Ivorra et a!., 1992; Komas et a!., 1993) . A variety of PDE III inhibitors produce complete, endothelium independent relaxation in precontracted rat aorta (Komas et ai., 1991) and potentiate the vasorelaxant effects of isoprenaline (Lindgren et ai., 1990 ). In con trast, selective PDE IV inhibitors alone had modest endothelium-dependent vasorelaxant properties (Komas et ai., 1991) and did not potentiate isoprena line vasorelaxation (Lindgren et ai., 1990) .
The regulation of cAMP hydrolysis is also impor tant in modulating the vascular tone in the eNS (Su zuki et ai., 1988; Parfenova et ai., 1993) ; however, the PDE isozymes that regulate cAMP in cerebral vessels have not been well characterized. The super fusion of selective PDE III and IV inhibitors on mouse and cat pial arteries produced mild to moder ate vasodilation, respectively (Parfenova et ai., 1993; Rosenblum et ai., 1993) .
The purpose of the present study was to identify and characterize the cAMP PDE isozymes (PDE III and IV) in a major cerebral artery and to assess their functional role. Specifically, selective PDE inhibitors denbufylline, (:±:) rolipram, and BRL-61063 ( Fig. 1) were evaluated for their effects on (1) cerebrovascu lar cAMP hydrolysis, (2) spasmogen-induced con tractions in isolated canine cerebral vessels, and (3) acute and chronic cerebral vasospasm in a model of subarachnoid�hemorrhage (SAH).
MATERIALS AND METHODS
Separation and partial purification of PDE isozymes from canine basilar arteries Tissue preparation. Basilar arteries were pooled (n = 8), and PDE isozyme separations and partial purifica tion were performed according to Torphy and Cieslinski (1990) . Briefly, the arteries were quickly frozen in liquid N2 and stored at -70°C until being used. All further proce dures were performed at 4°C. The arteries were chopped and homogenized with a Brinkman PT 10/35 polytron in 10 vol of buffer (pH 6.5) containing 20 mM bis-Tris, 2.5 mM dithiothretol, 10 mM ethylenediaminetetra-acetic acid (EDTA), 0.1 % Triton x-IOO, plus a protease inhibitor mix ture of 2 mM benzamidine, 20 p,g/ml of soybean trypsin inhibitor, 100 p,g/ml of bacitracin, 100 p,M p-tosyl-L-lycine chloromethyl ketone, 100 nM leupeptin, and 50 p,M phenyl methylsulphonyl fluoride. The homogenate was centri fuged at 20,000 g for 30 min, and the supernatant was applied to a DEAE-Sepharose CL-6B (Pharmacia Fine Chemicals, Inc. Piscataway, NJ, U.S.A.) column for the separation of PDE activities.
DEAE-Sepharose chromatography. PDE isozyme separation was performed on a DEAE-Sepharose column (1.6 cm i.d.) with a 10-ml bed volume equilibrated with homogenization buffer. A sample of the 20,000 g superna tant (1.8 ml) was applied to the column, followed by a wash with 25 ml of homogenization buffer. No detectable PDE activity was in this initial wash. The PDE isozymes then were eluted with 50 ml of a linear (0-1.0 M) sodium acetate Phosphodiesterase assay. Phosphodiesterase activity was determined as described previously (Torphy and Cies linski, 1990) . The reaction was conducted in a O.l-ml buffer containing (final concentration) 50 mM Tris-HCI buffer (pH 7.5), 5 mM MgCI2, 50 p,M 5T 4 C]AMP, or 50 p,M 5' [1 4 C]GMP (�400 dpm/nmol) as carrier and for recovery of product, 1 p,M [3H]cAMP or 1 p,M [3H]cG MP (�2,000 dpm/pmol), and enzyme. The reaction was initiated with either enzyme or substrate and conducted at 30°C. Incuba tion time varied depending on the amount of enzyme activ ity. The reaction was terminated by placing reaction vessels in a 100°C heating block for 1 min before they were placed in an ice bath. Cyclic nucleotide substrates were separated from 5' -nucleotide products by using polyacrylamide boronate gel columns according to the method of Davis and Daly (1979) . The 5'-monophosphate products were eluted with 8 ml of 0.25 M acetic acid into a scintillation vial containing 10 ml of Beckman Ready Solv-MP scintillation cocktail. Radioactivity was measured via scintillation spec troscopy. Recovery of 5' -[3H]AMP and 5' -[3H]GMP, as determined with the 5' -[l 4 C]AMP or 5' _[1 4 C]GMP, was 80 to 90%.
Isolated canine cerebral vessels
The methods used to investigate vasorelaxation in iso lated segments of canine cerebral arteries have been de scribed in detail elsewhere (Willette et aI., 1994) . Briefly, adult mongrel dogs were killed via i.v. pentobarbital over dose, and basilar, middle cerebral, and anterior spinal arter ies were carefully dissected into a Krebs-Henseleit buffer (composition below). Ring segments (2-3 mm long) were prepared from each vessel with the endothelium intact and suspended for isometric tension recordings in (Grass FT.03, Quincy, MA, U.S.A.) in 50-ml organ baths containing aer ated (95% 02/5% CO2) Krebs-Henseleit buffer (in mmollL: NaCl, 119; KCI, 4.7; KH2P0 4 , 1.2; CaCh, 2.5; MgS0 4 ' 1.5;
NaHC0
3 , 25 and glucose, 11) maintained at 38°C. An optimum resting tension of 750 mg was applied to each segment and equilibrated for 45 min before testing. The reactivity of each vascular segment was determined by in creasing the concentration of KCI (by addition to the bath) in the bath buffer to 60 mmollL to induce contraction and by adding arginine-vasopressin (100 nM) to produce an endothelium-dependent relaxation. After washing the tis sue complete�y, submaximal (�80%) concentrations of spasmogens (U46619, a thomboxane mimetic; oxyhemoglo bin; and endothelin-l) were used to contract tissues for vasorelaxation experiments. In some experiments, sponta neous tone was allowed to develop. Pretreatments (e.g., L NAME, a NOS inhibitor; and aminophylline, a nonselec tive adenosine antagonist) were added to the bath and equilibrated for 30 min before constructing a cumulative concentration-relaxation curves with selective PDE inhibi tors [denbufylline, (::,:: ) rolipram, siguazodan, zaprinast]. In some basilar segments, the endothelium was removed by gently rolling the artery over a rod placed in its lumen. Vasorelaxation was expressed as the percent of the spasmogen-induced tension, and potency was estimated by comparison of the concentrations need to produce 50% relaxation (EC50s) or corresponding values.
Canine hemorrhage models of chronic and acute cerebral vasospasm
The 35 male mongrel dogs used for these experiments weighed 10 to 12 kg and were housed in an accredited laboratory animal facility. All procedures were performed in accordance with the Guide for Care and Use of Labora tory Animals (DHEWIDHHS Publication no. NIH 85-23) and were approved by the Institutional Animal Care and Use Committee at Smith Kline Beecham Pharmaceuticals.
The procedure employed for producing delayed cerebral vasospasm was similar to the two-hemorrhage model de scribed by Chyatte et al. (1983) . On day 1, anesthesia was induced in all dogs by administering thiamylal sodium (8 mglkg, i.v.). The dogs were intubated immediately and placed supine on a heated fluoroscopy table. Anesthesia then was maintained by mechanical ventilation with isoflurane (2.5% in oxygen), and the femoral artery was exposed using aseptic technique. A hemostasis device (Cor- Immediately after the second angiogram, infusions of vehi cle (5% polyethylene glycol 200) or denbufylline, BRL-61063, or (::,:: ) rolipram were begun, and angiograms were repeated and compared at 30 and 60 min after the infusion to pretreatment angiograms demonstrating acute vaso spasm. Acute vasospasm was quantified as indicated above. 
Drugs and dose regimens

Statistical analysis
All values were expressed as the mean ±: the standard deviation (SD). Multiple treatments were compared with an analysis of variance, followed by a Bonferroni t test. IC50 values were calculated by a four-parameter logistic curve fitting routine which best described the data (GraFit, 3.01, Erithicus Software Ltd.). Vehicle and treatment re sults were compared with an unpaired and, in some cases, a paired Student's t test. Differences were considered statis tically significant at p :=:; 0.05.
RESULTS
D EAE-Sepharose chromatography
The elution profile of cAMP PDEs obtained from pooled canine basilar arteries (n = 8) is shown in Fig. 2 . DEAE chromatography of the soluble fraction produced one major peak of [3H]cAMP hydrolysis at 0.5 M sodium acetate and one minor peak at 0.1 M sodium acetate ( Fig. 2A and B) . The hydrolysis of cAMP was reduced in column fractions from the large peak by cGMP, siguazadon, (:±:: ) rolipram, and the combination of siquazadon and rolipram. The area analysis of the cAMP hydrolysis peaks indicates that the inhibitory activity of cGMP (25%) = siguazo dan (26%) < (:±:: ) rolipram (39%) < siguazodan and rolipram (95%). These results suggest that cAMP hydrolysis was mediated by PDE IV predominantly and, to a lesser extent, by PDE III. The addition of Ca++/calmodulin stimulated several-fold the small peak observed at 0.1 M sodium acetate and produced a shoulder of activity at 0.25 M sodium acetate ( Fig.  2A) . These results suggest that this peak contains one or more PDE I subtypes. It is noteworthy that cGMP did not produce the expected increase in cAMP hydrolysis in column fractions at 0.3 M sodium acetate, suggesting a lack of PDE II activity in the basilar artery.
Further characterization of the effects of PDE IV inhibitors was obtained by assessing PDE activity in fractions (34-44) pooled from the large 0.5 M sodium acetate peak (Fig. 3) . In the presence of siguazodan (10 p.M), the selective PDE IV inhibitors, BRL-61063, (:±:: ) rolipram, and denbufylline produced com plete concentration-related inhibition of PDE activ ity (ICsos = 0.21 :±:: 0.05 p.M, 0.67 :±:: 0.23 p.M, and 0.73 :±:: 0.16 p.M, respectively). Thus, BRL-61063, (:±:: ) rolipram, and denbufylline were potent, and effica cious inhibitors of partially purified PDE IV were obtained from the canine basilar artery.
Functional effects of PDE inhibitors in the canine basilar artery in vitro
In isolated ring segments of the canine basilar ar tery, denbufylline (a selective PDE IV inhibitor pro- totype) produced complete concentration-related re laxation when the tissues were precontracted with submaximal concentrations of several spasmogens as well as a spontaneously developed tone (Fig. 4A) . The ICsos produced by denbufylline in vessels pre contracted w ith U46619 (10 nM), oxyhemoglobin (1 J.LM), endothelin-1 (10 nM), and spontaneous tone were 144 ± 4 nM, 17 ± 15 nM, 21 ± 14 nM, and 5 ± 3 nM, respectively. Similar results were observed in segments obtained from the canine middle cerebral artery and anterior spinal artery (data not shown).
The vasorelaxant effects of selective PDE inhibi tors were also compared in canine basilar arteries precontracted with U46619 (10 nM). The selective PDE IV inhibitors, denbufylline (ICso = 144 ± 4 nM), (±) rolipram (ICso = 73 ± 9 nM), and BRL-61063 (ICso = 36 ± 21 nM) produced complete con centration-related relaxation (Fig. 4B) . In contrast, the selective PDE V inhibitor zaprinast and the selec tive PDE III inhibitor siguazodan produced only weak vasorelaxation of the canine basilar artery (ICsos = 4.5 ± 2.4 J.LM and> 10 J.LM, respectively).
The mechanism of vasorelaxation produced by PDE IV inhibitors was explored in canine basilar arteries precontracted with U46619 (10 nM). Spe cifically, the role of the endothelium in mediating denbufylline-and (±) rolipram-induced vasorelax ation was evaluated in arteries in which the endothe lium was removed mechanically. The lack of endothe lium-dependent vasorelaxation mediated by arginine vasopressin (100 nM) was used to confirm removal of the endothelium (data not shown). The concentra tion-dependent relaxation produced by denbufylline was similar in intact (ICso = 144 ± 4 nM) and de nuded (ICso = 322 ± 304 nM) basilar arteries ( 5). Pretreatment with L-NAME (100 J.LM), a nitric oxide synthase inhibitor, was also effective in inhibit ing the endothelium-dependent vasorelaxation in duced by AVP (100 nM); however, L-NAME did not reduce the vasorelaxant potency of denbufyl line (ICso = 47 ± 2 nM) but reduced slightly maxi mal relaxation (Fig. 5 ). In addition, aminophylline (1 J.LM), a nonselective adenosine receptor antago nist, did not inhibit denbufylline-induced (ICso = 36 ± A. In canine basilar artery segments precontracted with U46619 (10 nM), vasorelaxation induced by denbufylline was compared in blood vessels pretreated with I-NAME (1 00 �M) or aminophylline (1 �M) and with intact or denuded endothelium. Each group contained basilar arteries segments from three to seven dogs and two to four observations per blood vessel. All values are the mean:+:: SO .• p < 0.05 compared to the correspond ing response in the intact group.
4 nM) vasorelaxation (Fig. 5) . These results suggest that the endothelium and adenosine receptors do not play a significant role in the relaxation of the canine basilar artery produced by PDE IV inhibitors. Similar results were obtained in experiments performed with (±) rolipram (n = 2).
Effect of PDE IV inhibitors on cerebral vasospasm in vivo
In the acute cerebral vasospasm model, the intra cisternal administration of autologous blood pro duced a significant reduction in the cross-sectional area of the basilar and anterior spinal arteries ( Fig.  6A and B ) within 30 to 60 min. The acute vasospasm persisted throughout the experiment (2:3 h) and was uneffected by vehicle (5% polyethylene glycol 200) infusion (data not shown). In contrast, the adminis tration of selective PDE IV inhibitors, denbufylline (10 ILg/kg, i.v. bolus plus 3 ILg/kg/min for 1 h), (±) rolipram, (10 ILg/kg, i.v. bolus plus 1 ILg/kg/min for 1 h), and BRL-61063 (10 ILg/kg, i.v. bolus + 1 ILg/ kg/min for 1 h) produced a significant reversal of the acute vasospasm when angiograms were repeated at the conclusion of the infusion (Fig. 6A and B) . None of the PDE IV inhibitors employed had a significant effect on mean arterial blood pressure ( Fig. 7 A) ; however, all three compounds increased heart rate moderately throughout the infusion period (Fig. 7B) .
In the two-hemorrhage model of chronic cerebral vasospasm, a severe spasm was observed consistently in the basilar and anterior spinal arteries on day 7 (Fig. SA) . Placebo treatment (5% polyethylene glycol 200 i.v. infusion for 1 h on days 1 and 7, plus lactose capsules, p.o., b.i.d. on days 2-6) had no effect on the development of cerebral vasospasm (similar to historic controls). Treatment with BRL-61063 (10 ILg/ kg i.v. bolus plus 1 ILg/kg/min for 1 h on days 1 and 7; 0.2 mg/kg, p.o., b.i.d. on days 2-6) also had no significant effect on the development of cerebral va sospasm when compared with the placebo group (Fig.  SB ). An increase in the incidence of emesis prevented further dose escalation with BRL-61063. Denbufylline-induced in vitro vasorelaxation was compared in basilar artery segments prepared from some of the 7 day SAH placebo group in Fig. S and basilar artery segments obtained from a naive group. Vasorelaxation produced by denbufylline was im paired significantly in the basilar artery segments ob tained from the subarachnoid hemorrhage ( Fig. 9 ).
There was approximately a 10-fold reduction in den bufylline's potency (ICso = 144 ± 4 nM; naive group versus ICso = 1,345 ± 205 nM; SAH group). A similar impairment of ( +) rolipram-induced vasorelaxation (n = 1) also was observed in basilar segments ob tained from the 7-day SAH placebo group (data not shown).
DISCUSSION
The present study indicates that the PDE IV iso zyme plays an important role in mediating vasorelax ation in large cerebral arteries and suggests that this mechanism is compromised in chronic cerebral vaso spasm associated with subarachnoid hemorrhage. The cAMP/PDE isozyme profile in the canine basilar artery demonstrates that cAMP hydrolysis was cata lyzed by PDE IV activity and, to a lesser extent, PDE III activity. Selective inhibition of both PDE III and IV abolished cAMP hydrolysis in the basilar artery. This cAMP PDE isozyme profile appeared similar to that reported in bovine aortic smooth muscle (Ivorra et aI., 1992) . It is noteworthy that little or no PDE II was demonstrable in the canine basilar artery. The significance of this observation remains to be deter mined.
In canine basilar artery segments, selective PDE IV inhibitors (denbufylline, BRL 61063, and rolipram) produced complete and potent relaxation in arteries contracted by spontaneous tone as well as oxyhemo globin, U46619 (thromboxane mimic), and endo thelin-I, all proposed mediators of cerebral vaso spasm (Steele et aI., 1991; Satoh et aI., 1991; Willette et aI., 1994) . Thus, the relaxant effects of PDE IV inhibitors are not limited to inhibition of a specific spasmogen and are consistent with their known mechanism of action. In fact, the vasorelaxant effects were observed over approximately the same range of concentrations needed to inhibit the POE IV iso zyme in the canine basilar artery. In addition, the vasorelaxant potency and efficacy of all three selec tive POE IV inhibitors were significantly greater than the selective POE III inhibitor siguazodan and the selective POE V inhibitor zaprinast. These results were consistent with the relative preponderance of the POE IV isozyme in the canine basilar artery. In contrast, the relaxant effects of selective POE IV inhibitors alone have been shown to be modest, at best, in a variety of peripheral vascular segments in vitro (Lindgren et ai, 1990; Lindgren and Andersson, 1991; Komas et aI., 1991) . For example, ( :::,: :: ) rolipram produced only slight relaxation in rat and human coronary and pulmonary arteries but showed more (35%) relaxation in rat and human renal arteries (Lindgren and Andersson, 1991) ; however, the mod est relaxation produced by selective POE IV inhibi tors in the rat aorta is potentiated considerably by J Cereb Blood Flow Metab, Vol. 17, No.2, 1997 agents that increase cAMP and cGMP (Komas et aI., 1991) . Under these conditions, both endothelium dependent and independent relaxation can be dem onstrated. Oenbufylline and ( :::,: :: ) rolipram were used as proto typic POE IV inhibitors to address the potential mechanisms of vasorelaxation in the canine basilar artery. Pretreatment with aminophylline, a nonselec tive adenosine receptor antagonist, had no significant effect on the vasorelaxant potency and efficacy of POE inhibitors. It was important to perform this ex periment given the known, albeit weak, interactions of some adenosine-like POE IV inhibitors with aden osine receptors and reuptake sites (Nicholson et aI., 1989) . These results suggest that the vasorelaxant effects of POE IV inhibitors are not mediated indi rectly through an accumulation of adenosine or via direct interactions with adenosine receptors. In addi tion, the vasorelaxation produced by POE IV inhibi tors was not dependent on a functional intact endo thelium. Endothelium-independent relaxation has also been reported for IBMX, a nonselective POE inhibitor, in the rat and canine basilar artery (Nishi mura et aI., 1992; Cosentino et aI., 1992) . Surprisingly, pretreatment with L-NAME, a nitric oxide synthetase inhibitor, produced a small but significant reduction in the denbufylline maximum response. Similar re sults were reported for the suffusion of a PDE IV inhibitor (RO-201724) on mouses pial arteries fol lowing endothelial damage and L-NMMA (Rosen blum et aI., 1993). Cerebral vasospasm associated with subarachnoid hemorrhage is believed to involve both vasoconstric tion and vascular remodelling of large cerebral arter ies surrounded by the thick abluminal blood clot (Kim et aI., 1989) . The ability of PDE IV inhibitors to produce (a) potent vasorelaxation of spasmogens thought to be of importance in cerebral vasospasm (herein), (b) inhibition of vascular smooth-muscle proliferation (Takahashi et aI., 1992; Souness et aI., 1992) , and (c) inhibition of TFN-a production (Kap lan et aI., 1995) led to the proposal that selective PDE IV inhibitors may limit cerebral vasospasm by inhibiting vasoconstriction and vascular remodelling in vessels affected by subarachnoid hemorrhage. In a canine model of acute cerebral vasospasm, all three selective PDE IV inhibitors (denbufylline, (±) roli pram, and BRL 61063) reversed the acute basilar spasm observed on days 1 and 2 (data not shown) after the intracisternal administration of autologous blood; however, chronic treatment with BRL-61063, an orally active, metabolically stable analog of denbu fylline (Kaplan et aI., 1995) , failed to prevent the development of basilar artery spasm in a 7-day two hemorrhage canine model of chronic cerebral vaso spasm. These results suggest that the development of acute cerebral vasospasm is not a prerequisite for chronic vasospasm, as PDE IV inhibitors clearly re verse acute cerebral vasospasm, at least during the first 2 days after SAH. In addition, the vasorelaxant potency of denbufylline was significantly reduced (�lO-fold) in isolated segments of vasospastic basilar arteries obtained on day 7 from the SAH group. The results also suggest that the pathomechanisms underlying chronic cerebral vasospasm differ from acute cerebral vasospasm and may limit, either di rectly or indirectly, cAMP-dependent vasorelaxation.
It was shown previously that vasorelaxation and cAMP generation produced by vasoactive intestinal polypeptide ,.and calcitonin gene-related peptide are comprised in isolated basilar arteries from a rabbit model of subarachnoid hemorrhage (Tsukahara et aI., 1989; Sutter et aI., 1995) . In addition, Kim et al. (1992) also demonstrated impaired nitric oxide-mediated vas ore laxation in basilar arteries obtained from the ca nine chronic SAH model. These investigators deter mined that the altered cGMP-dependent relaxation was related to an impaired activation of soluble gua nylate cyclase and not to cGMP insensitivity. Perhaps a similar impairment of adenylate cyclase regulation may account for the reduced potency and efficacy of PDE IV inhibitors in chronic cerebral vasospasm.
In conclusion, cAMP appears to be an important modulator of cerebrovascular tone, and the PDE IV isozyme plays a prominent role in the hydrolysis of cAMP in large cerebral arteries. In addition, selective PDE IV inhibitors produce potent and efficacious endothelium-independent vasorelaxation in these vessels both in vitro and in vivo. Finally, the vaso modulatory effects of PDE IV are significantly im paired in chronic cerebral vasospasm associated with SAH. This conclusion does not preclude the possibil ity that PDE IV inhibitors with fewer dose-limiting side effects may yet prove useful for the treatment of chronic cerebral vasospasm in SAH. 
